You are here

  • Home
  • Archive
  • Volume 25, Issue Suppl 1
  • 4CPS-149 Time of permanence in second or successive lines of treatment with anti-tnf drugs vs other biological drugs in patients with inflammatory arthropathies

Article info

Article menu
Download PDFPDF
Section 4: Clinical pharmacy services
4CPS-149 Time of permanence in second or successive lines of treatment with anti-tnf drugs vs other biological drugs in patients with inflammatory arthropathies

Authors

Citation

Bello MS, Salvia PL, Caudevilla MH, et al
4CPS-149 Time of permanence in second or successive lines of treatment with anti-tnf drugs vs other biological drugs in patients with inflammatory arthropathies
European Journal of Hospital Pharmacy 2018;25:A111-A112.

Publication history

  • First published March 2, 2018.
Online issue publication 
April 21, 2018

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© 2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions